PortfoliosLab logoPortfoliosLab logo
AXON vs. CORT
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

AXON vs. CORT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Axon Enterprise, Inc. (AXON) and Corcept Therapeutics Incorporated (CORT). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, AXON achieves a -17.06% return, which is significantly lower than CORT's 110.72% return. Over the past 10 years, AXON has outperformed CORT with an annualized return of 35.39%, while CORT has yielded a comparatively lower 29.33% annualized return.


AXON

1D
-3.10%
1M
16.73%
YTD
-17.06%
6M
-14.84%
1Y
-40.51%
3Y*
34.22%
5Y*
26.05%
10Y*
35.39%

CORT

1D
0.98%
1M
40.26%
YTD
110.72%
6M
-11.63%
1Y
5.36%
3Y*
46.50%
5Y*
27.35%
10Y*
29.33%
*Multi-year figures are annualized to reflect compound growth (CAGR)

AXON vs. CORT - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
AXON
Axon Enterprise, Inc.
-17.06%-4.44%130.06%55.69%5.69%28.13%67.21%67.50%65.09%9.32%
CORT
Corcept Therapeutics Incorporated
110.72%-30.94%55.14%59.92%2.58%-24.31%116.20%-9.43%-26.02%148.76%

Correlation

The correlation between AXON and CORT is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.09

Correlation (3Y)
Calculated over the trailing 3-year period

0.17

Correlation (5Y)
Calculated over the trailing 5-year period

0.22

Correlation (10Y)
Calculated over the trailing 10-year period

0.20

Correlation (All Time)
Calculated using the full available price history since Apr 14, 2004

0.17

The correlation between AXON and CORT shifts across timeframes, from 0.09 (1 year) to 0.22 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

AXON:

$38.85B

CORT:

$7.66B

EPS

AXON:

$2.41

CORT:

$0.41

PE Ratio

AXON:

195.83

CORT:

178.81

PEG Ratio

AXON:

0.06

CORT:

89.07

PS Ratio

AXON:

13.54

CORT:

11.07

PB Ratio

AXON:

10.99

CORT:

12.00

Total Revenue (TTM)

AXON:

$2.98B

CORT:

$769.10M

Gross Profit (TTM)

AXON:

$1.77B

CORT:

$755.64M

EBITDA (TTM)

AXON:

$156.24M

CORT:

$3.66M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

AXON vs. CORT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AXON
AXON Risk / Return Rank: 1414
Overall Rank
AXON Sharpe Ratio Rank: 1111
Sharpe Ratio Rank
AXON Sortino Ratio Rank: 1313
Sortino Ratio Rank
AXON Omega Ratio Rank: 1313
Omega Ratio Rank
AXON Calmar Ratio Rank: 1717
Calmar Ratio Rank
AXON Martin Ratio Rank: 1616
Martin Ratio Rank

CORT
CORT Risk / Return Rank: 4747
Overall Rank
CORT Sharpe Ratio Rank: 4444
Sharpe Ratio Rank
CORT Sortino Ratio Rank: 4747
Sortino Ratio Rank
CORT Omega Ratio Rank: 5656
Omega Ratio Rank
CORT Calmar Ratio Rank: 4444
Calmar Ratio Rank
CORT Martin Ratio Rank: 4444
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AXON vs. CORT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Axon Enterprise, Inc. (AXON) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


AXONCORTDifference
Sharpe ratioReturn per unit of total volatility

-0.80

Sortino ratioReturn per unit of downside risk

-1.59

Omega ratioGain probability vs. loss probability

0.88

1.14

-0.25

Calmar ratioReturn relative to maximum drawdown

-0.67

0.08

-0.76

Martin ratioReturn relative to average drawdown

-1.17

0.15

-1.32

AXON vs. CORT - Sharpe Ratio Comparison

The current AXON Sharpe Ratio is -0.73, which is lower than the CORT Sharpe Ratio of 0.07. The chart below compares the historical Sharpe Ratios of AXON and CORT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


AXONCORTDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.73

0.07

-0.80

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.55

0.37

+0.18

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.72

0.44

+0.28

Sharpe Ratio (All Time)

Calculated using the full available price history

0.51

0.11

+0.40

Drawdowns

AXON vs. CORT - Drawdown Comparison

The maximum AXON drawdown since its inception was -91.78%, roughly equal to the maximum CORT drawdown of -94.28%. Use the drawdown chart below to compare losses from any high point for AXON and CORT.


Loading charts...

Drawdown Indicators


AXONCORTDifference

Max Drawdown

Largest peak-to-trough decline

-91.78%

-94.28%

+2.50%

Max Drawdown (1Y)

Largest decline over 1 year

-60.28%

-64.40%

+4.12%

Max Drawdown (3Y)

Largest decline over 3 years

-60.28%

-71.85%

+11.57%

Max Drawdown (5Y)

Largest decline over 5 years

-60.28%

-71.85%

+11.57%

Max Drawdown (10Y)

Largest decline over 10 years

-60.28%

-71.85%

+11.57%

Current Drawdown

Current decline from peak

-45.92%

-35.80%

-10.12%

Average Drawdown

Average peak-to-trough decline

-43.59%

-53.44%

+9.85%

Ulcer Index

Depth and duration of drawdowns from previous peaks

34.81%

35.34%

-0.53%

Volatility

AXON vs. CORT - Volatility Comparison

Axon Enterprise, Inc. (AXON) has a higher volatility of 19.02% compared to Corcept Therapeutics Incorporated (CORT) at 16.41%. This indicates that AXON's price experiences larger fluctuations and is considered to be riskier than CORT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


AXONCORTDifference

Volatility (1M)

Calculated over the trailing 1-month period

19.02%

16.41%

+2.61%

Volatility (6M)

Calculated over the trailing 6-month period

44.22%

85.07%

-40.85%

Volatility (1Y)

Calculated over the trailing 1-year period

55.73%

76.73%

-21.00%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

47.97%

74.52%

-26.55%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

49.19%

67.22%

-18.03%

Dividends

AXON vs. CORT - Dividend Comparison

Neither AXON nor CORT has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

AXON vs. CORT - Financials Comparison

This section allows you to compare key financial metrics between Axon Enterprise, Inc. and Corcept Therapeutics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M20222023202420252026
807.35M
164.90M
(AXON) Total Revenue
(CORT) Total Revenue
Values in USD except per share items

AXON vs. CORT - Profitability Comparison

The chart below illustrates the profitability comparison between Axon Enterprise, Inc. and Corcept Therapeutics Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%70.0%80.0%90.0%100.0%20222023202420252026
59.1%
98.3%
Portfolio components
AXON - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Axon Enterprise, Inc. reported a gross profit of 477.29M and revenue of 807.35M. Therefore, the gross margin over that period was 59.1%.

CORT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a gross profit of 162.02M and revenue of 164.90M. Therefore, the gross margin over that period was 98.3%.

AXON - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Axon Enterprise, Inc. reported an operating income of 29.24M and revenue of 807.35M, resulting in an operating margin of 3.6%.

CORT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported an operating income of -49.60M and revenue of 164.90M, resulting in an operating margin of -30.1%.

AXON - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Axon Enterprise, Inc. reported a net income of 169.31M and revenue of 807.35M, resulting in a net margin of 21.0%.

CORT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a net income of -31.20M and revenue of 164.90M, resulting in a net margin of -18.9%.


Frequently Asked Questions


AXON and CORT have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AXON has higher volatility (19.02%) compared to CORT (16.41%). In terms of maximum drawdown, AXON dropped -91.78% vs CORT's -94.28%.

CORT currently has the higher Sharpe Ratio (0.07 vs -0.73), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for AXON and CORT

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer